Abstract-Vascular injury initiates a cascade of phenotype-altering molecular events. Transcription factor function in this process, particularly that of negative regulators, is poorly understood. We demonstrate here that the forced expression of the injury-inducible GLI-Krüppel zinc finger protein Yin Yang-1 (YY1) inhibits neointima formation in human, rabbit and rat blood vessels. YY1 inhibits p21 WAF1/Cip1 transcription, prevents assembly of a p21 WAF1/Cip1 -cdk4-cyclin D1 complex, and blocks downstream pRb Ser249/Thr252 phosphorylation and expression of PCNA and TK-1. Conversely, suppression of endogenous YY1 elevates levels of p21 WAF1/Cip1 , PCNA, pRb Ser249/Thr252 and TK-1, and increases intimal thickening. YY1 binds Sp1 and prevents its occupancy of a distinct element in the p21 WAF1/Cip1 promoter without YY1 itself binding the promoter. Additionally, YY1 induces ubiquitination and proteasome-dependent degradation of p53, decreasing p53 immunoreactivity in the artery wall. These findings define a new role for YY1 as both an inducer of p53 instability in smooth muscle cells, and an indirect repressor of p21 WAF1/Cip1 transcription, p21 WAF1/Cip1 -cdk4-cyclin D1 assembly and intimal thickening. njury to the blood vessel wall initiates a cascade of molecular events that includes the induction of transcriptional activators and repressors. The net balance in the activities of these regulators in the reparative response to injury governs the phenotypic outcome, which includes vascular disorders such as atherosclerosis, bypass graft failure, hemodialysis access graft failure, restenosis after percutaneous coronary angioplasty and/or stenting -the pathogenesis of each of which involves the formation of a smooth muscle cell (SMC)-rich intima. The roles played by transcriptional regulators controlling these processes are only partly defined. Greater mechanistic insights would provide an invaluable basis for novel targeted interventional approaches.
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Yin Yang-1 (YY1 [also known as ␦], NF-E1, UCRBP and CF1]) 1,2 was first identified on the basis of its capacity to negatively regulate the adeno-associated virus P5 promoter, 3 the immunoglobulin kappa 3Ј enhancer 4 and the upstream conserved long terminal repeat region of Moloney murine leukemia virus. 5 This GLI-Krüppel zinc finger protein plays a regulatory role in a variety of fundamental biological processes, such as growth, apoptosis and differentiation. This is, at least in part, because of its capacity to influence gene expression via its ability to initiate, activate or repress transcription depending on the context in which it binds. YY1 regulates transcription by direct or indirect activation or repression via cofactor recruitment and/or disruption of binding sites causing conformational changes in DNA. 1, 2, 6 El Affar et al 7 recently used genome-wide expression profiling to identify a plethora of YY1 target genes (primary and secondary) implicated in cell proliferation, cytokinesis, apoptosis, development, and differentiation. Levels of the cyclin-dependent kinase inhibitor, p21 WAF1/Cip1 increased 3.3-fold in hypomorphic mice expressing 25% of normal YY1 levels, 7 suggesting an inverse relationship between the transcription factor and the cell cycle regulator. This is notionally consistent with our previous demonstration in SMCs of YY1 inhibition of cell proliferation. 8 Other studies, however, have linked YY1 with increased cell growth, prompting some to propose YY1 as a therapeutic target in cancer. 6, 9 In this study, we explored the relationship between YY1 and p21 WAF1/Cip1 transcription in SMC growth and intimal thickening after arterial injury.
We demonstrate here that YY1 blocks p21 WAF1/Cip1 transcription in SMCs by preventing Sp1 occupancy of a distinct element upstream in the p21 WAF1/Cip1 promoter, thereby perturbing assembly of a p21 WAF1/Cip1 -cdk4-cyclin D1 complex, blocking pRb Ser249/Thr252 phosphorylation, E2F-dependent gene expression and intimal thickening. In addition, we show that YY1 destabilizes p53, a positive regulator of p21 WAF1/Cip1 transcription by inducing its ubiquitination and proteasomal degradation.
Materials and Methods
Methodologies used for adenoviral YY1 construction, human saphenous vein culture and transfection, cell culture and plasmid transfection, proliferation assays, carotid artery injury and adenovirus delivery, rabbit collar model and periadventitial gene transfer, immunohistochemical staining, transient transfection and reporter gene analysis, Western blot analysis, immunoprecipitation analysis, RT-PCR, EMSA and ChIP are described in the online supplement available at http://circres.ahajournals.org.
Results

YY1 Inhibits Intimal Thickening in Human, Rabbit and Rat Blood Vessels
YY1, like many other transcription factors, is inducibly expressed in vascular SMCs within hours of balloon injury. 8 However, whether this zinc transcription factor influences intimal thickening or plays a gene regulatory role in injured vessels is unknown. We explored these questions given the apparent paradox between the growth-promoting properties of YY1 in non-SMC types 6, 9 and the inverse relationship between YY1 and the cyclin-dependent kinase inhibitor p21 WAF1/Cip1 in hypomorphic mice. 7 Adenoviral overexpression of YY1 (Ad-YY1), but not LacZ (Ad-LacZ), inhibited intimal thickening in explants of human saphenous veins, commonly used as autologous conduits for CABG 10 within 14 days (Figure 1a & supplemental Figure I ). Consistent with these observations, Ad-YY1 also blocked rabbit and rat primary SMC proliferation (Figure 1b ), but intriguingly, had no effect on vascular endothelial cell growth (Figure 1b) . YY1 inhibition of SMC proliferation in vitro or neointima formation was not associated with increased apoptosis, as determined by assessment of internucleosomal DNA fragmentation or terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) immunostaining (data not shown).
We next used 2 well-established animal models of SMC hyperplasia to determine the effect of YY1 on intimal thickening in intact arteries. YY1 inhibited neointima formation in rabbit carotid arteries 9 days after periadventitial collar placement 11 ( Figure 1c ) and in rat carotid arteries 14 days after balloon catheter injury 12 (Figure 1d ), coincident with reduced SMC numbers in the neointima (Figure 1, c and d , right panels). We also observed no difference in intensity of 10 pfu/mL of Ad-YY1 or Ad-LacZ in medium containing 30% fetal bovine serum. IEL, internal elastic lamina. b, Primary rabbit or rat aortic SMCs or bovine aortic ECs (EC) were transduced with Ad-YY1 or Ad-LacZ at the indicated multiplicities of infection (MOI) and grown in the presence of serum for 48 hour before quantitation of cell suspensions in an automated Coulter counter. SFM denotes serum-free medium. c, Effect of Ad-YY1 on intimal hyperplasia in rabbit collared carotid arteries. Ratios were determined 9 days after collar placement and gene transfer in arteries transduced with Ad-YY1 or Ad-LacZ. Figure shows representative H&E-stained cross-sections. IEL, internal elastic lamina. d, Effect of exogenous YY1 on neointima formation in carotid arteries of rats 14 days following balloon injury and intraluminal transduction with Ad-YY1 or Ad-LacZ. SMC nuclei were quantitated in triplicate under high magnification (ϫ400) and expressed as numbers in the neointima (NI per high power field (HPF). *denotes P Ͻ0.05 compared with control.
immunostaining for fibronectin and collagen type I, or staining with Masson's Trichrome or Alcian Blue per field of SMCs in the neointima between groups (data not shown), suggesting that YY1 negatively regulates intimal thickening primarily by reducing SMC proliferation rather than the matrix content as an independent variable.
YY1 Represses p21 WAF1/Cip1 Transcription in SMCs
In efforts to define the molecular basis for YY1 inhibition, we investigated whether YY1 perturbs a principal component of the cell cycle machinery. Immunohistochemical analysis revealed that YY1 overexpression in the artery wall decreased levels of p21 ). IEL, internal elastic lamina. b, Effect of YY1 on p21 WAF1/Cip1 protein and p21 WAF1/Cip1 promoter-dependent reporter gene expression. SMCs were transfected with 20 g of pCB6-YY1 or pCB6 ϩ in 100-mm plates and Western blot analysis was performed after 24 hour in the presence of serum (lower left and right panel ). NE demonstrates nuclear extracts; Cyto denotes cytosolic extracts. Alternatively, transfections were performed in 6-well plates with increasing amounts of pCB6 ϩ or pCB6-YY1 (0.5, 1 and 2 g) and 10 g of p21 WAF1/Cip1 promoter construct 3*6. Firefly luciferase activity was assessed after 24 hour (upper left panel). c, Effect of exogenous p21 WAF1/Cip1 on SMC proliferation inhibited by YY1. SMCs in 96-well plates were transfected with pCEP-WAF1 (0.75 g), pCEP (0.75 g), pCB6-YY1 (3 g) or pCB6
ϩ (3 g) and cell numbers were quantitated after 48 hour in the presence of serum. Alternatively, the cells were transfected in 100 mm dishes and Western immunoblot analysis was performed after 24 hour. d, Effect of YY1 overexpression on the growth of SMCs cotransfected with antisense oligonucleotides (ODN) directed to p21 WAF1/Cip1 (p21AS) or a control (p21CL). 13 SMCs in 96-well plates were transfected with 3 g of pCB6-YY1 or pCB6 ϩ together with 0.5 mol/L of p21AS or p21CL and cell numbers were quantitated after 72 hour in the presence of serum. Cell counts in the pCB6 ϩ / p21AS cohort were reduced compared with those of the pCB6 ϩ and pCB6 ϩ /p21CL groups. Alternatively, the cells were transfected in 100 mm dishes and Western blot analysis was performed after 24 hour. lation. 14 YY1 inhibited both formation of the complex and pRb Ser249/Thr252 phosphorylation ( Figure 3a ). These data show for the first time that YY1 inhibits p21 WAF1/Cip1 transcription and consequently, the formation of a cyclin D1-cdk4-p21 WAF1/Cip1 complex. In contrast, cyclin D1-cdk4-p21 WAF1/Cip1 assembly and pRb Ser249/Thr252 levels were unaltered by YY1 in ECs (Figure 3a) , consistent with the inability of YY1 to alter p21 WAF1/Cip1 expression in this cell type (Figure 3b ). promoter is located at bps Ϫ1975/Ϫ1270 (Figure 4a , upper panel). This region does, however bear an atypical motif ( 5Ј CCTCCC 3Ј ) previously uncharacterized in this promoter that supports the interaction of Sp1 with the smooth muscle myosin heavy chain promoter 16 and the lecithin:cholesterol acyltransferase promoter. 17 Mutation of this element (Sp1-7: Ϫ1375 CCTCCC Ϫ1370 to mSp1-7: 4c, middle and lower panels). In contrast, GST-YY1⌬ZNF lacking YY1's zinc finger region (which binds to the zinc finger region of Sp1 18, 19 ) failed to inhibit the interaction of Sp1 with the promoter (Figure 4c , lower panel). To further demonstrate specificity of YY1 inhibition, we performed ChIP analysis for the well-established Sp1-dependent gene, platelet-derived growth factor A-chain (PDGF-A) 20 in SMCs transfected with YY1. YY1 did not affect Sp1's interaction with a 777 bp region of the PDGF-A promoter containing Sp1-binding elements (SBE) 20 ( Figure 5d , upper panel), nor did it affect Sp1's interaction with the proximal SBE of the p21 WAF1/Cip1 promoter 21 ( Figure 5d , lower panel). These findings demonstrate that YY1 prevents Sp1 occupancy of a novel recognition element ( Ϫ1375 CCTCCC Ϫ1370 ) upstream in the p21 WAF1/Cip1 promoter in a site-selective manner. This mechanism of YY1 repression involving Sp1 displacement has hitherto not been described.
YY1 Represses
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YY1 siRNA Stimulates SMC Growth and Intimal Thickening
Because YY1 overexpression inhibits SMC proliferation and neointima formation after vascular injury, we reasoned that strategies reducing the expression of endogenous YY1 in the vessel wall would, conversely, increase SMC growth and intimal thickening. siRNA targeting YY1 abrogated seruminducible YY1 expression and increased p21 WAF1/Cip1 expression without affecting levels of GAPDH ( Figure 6a , right panel). The siRNA increased serum-inducible SMC proliferation within 3 days, whereas the nonsense (ns) siRNA counterpart had no effect ( Figure 6a , left panel). Moreover, the siRNA increased in the rat carotid artery intimal thickening 14 days after balloon injury beyond that of the nonsense or vehicle groups (Figure 6b ). Immunohistochemical analysis revealed that the siRNA suppressed YY1 expression in the artery wall while increasing levels of p21 WAF1/Cip1 , PCNA and pRb Ser249/Thr252 (Figure 6c and supplemental Figure III) . element in the p21 WAF1/Cip1 promoter. a, 5Ј deletion analysis using p21 WAF1/Cip1 promoter-luciferase constructs for the identification of a YY1-repression region and a YY1-response element. SMCs in 6-well plates were transfected with 10 g of construct 3*6, 7*3 or 3*6mSp1-7 and 3 g of pCB6-YY1 or pCB6
ϩ . Firefly luciferase activity was determined in the lysates after 24 hour and normalized to the backbone plasmid (pCB6) which was set at 100% (bottom left). Alternatively, the cells were transfected with 10 g of Sp1-7-pGL3-prom, mSp1-7-pGL3-prom or pGL3-prom and 3 g of CMV-Sp1 or CMV-gutless (lower right). b, EMSA was performed with SMC nuclear extracts (NE) and 32 P-Oligo p21 WAF1/Cip1 (Ϫ1387/Ϫ1358) or 32 P-Oligo MVYY1. Antibody (2 g) was added 10 minutes before the addition of the 32 P-labeled probe. Arrow indicates the nucleoprotein complex. c, ChIP analysis to determine the effect of overexpressing YY1, either as wild-type or GST-fusion protein. Human SMCs in 100-mm plates were transfected with 30 g of pCB6-YY1, pCB6
ϩ , pcDNA-GST-YY1, or pcDNA-GST-YY1⌬ZNF or pcDNA3.1 before chromatin immunoprecipitation and PCR. The 845 bp PCR product was sequenced and confirmed. No Ab indicates no antibody added.
YY1 Regulates Thymidine Kinase-1 Expression
Rb phosphorylation triggers transcription factor E2F release 14 which in turn activates thymidine kinase-1 (TK-1) stimulating salvage DNA synthesis and cell cycle progression. 22 We examined the influence of YY1 on events downstream of pRb Ser249/Thr252 phosphorylation and examined E2F-dependent TK-1 expression 14,23 as a surrogate measure of pRb Sp1 displacement may not be the only mechanism with which YY1 controls p21 WAF1/Cip1 . Previous studies have demonstrated that p53 positively regulates p21 WAF1/Cip1 . 24 We reasoned, therefore, that as well as causing Sp1 displacement, YY1 may reduce p21 WAF1/Cip1 expression via p53. p53 stability is regulated by Mdm2-mediated ubiquitination and degrada- tion via the proteasome. 25, 26 We found that YY1 overexpression reduces p53 immunoreactivity in SMCs, both in culture and in the artery wall (Figure 7c , left panel), consistent with our previous observation of an inverse relationship between p53 and YY1 expression in SMCs in the artery wall. 8 Coimmunoprecipitation analysis revealed that YY1 increased p53 ubiquitination (Figure 7c, top right panel) , as observed by Sui and coworkers in an osteosarcoma cell line. 27 This was accompanied by reduced p21 WAF1/Cip1 levels ( Figure 7c , top right panel). Experiments further showed that p53 accumulates in SMCs treated with the proteasome inhibitor MG132, and that blockade of the proteasome prevents YY1 suppression of p53 protein levels (Figure 7c, bottom right panel) . In contrast, p53 mRNA was not altered by YY1, either in the absence or presence of MG132 (Figure 7c, bottom right  panel) . These data thus demonstrate that YY1 suppression of p21 WAF1/Cip1 in SMCs also involves p53 ubiquitination and proteasomal degradation.
Discussion
We demonstrate here that YY1 inhibits intimal thickening in human, rabbit and rat blood vessels, and that YY1 inhibits p21 WAF1/Cip1 transcription in SMCs by preventing Sp1 occupancy of an element upstream in the p21 WAF1/Cip1 promoter, perturbing assembly of a p21 WAF1/Cip1 -cdk4-cyclin D1 complex, thereby blocking Rb phosphorylation. This study challenges the general dogma that p21 WAF1/Cip1 plays a negative regulatory role in cell cycle progression and provides a mechanism. 28 -34 The notion that p21 WAF1/Cip1 may function as a positive cell cycle regulator has been described before. 14, 35, 36 Weiss et al have shown that p21 WAF1/Cip1 is an assembly factor required for PDGF-induced vascular SMC proliferation. 37 Moreover, p21 WAF1/Cip1 expression is proatherogenic in apolipoprotein E-null mice, possibly as a consequence of cell cycle-independent activities of p21 WAF1/Cip1 . 38, 39 Using both gain-and loss-of-function approaches, we provide evi- ). The YY1 antibody was used at a lower dilution (ld; 1:100) than that used elsewhere (1:200) to better demonstrate siRNA suppression of YY1 expression; the DAB incubation time using the pRb Ser249/Thr252 antibody was shorter (sdab; 1 minute) compared with 2 minutes used elsewhere. IEL, internal elastic lamina. *denotes P Ͻ0.05 compared with control.
dence for YY1 regulation of p21 WAF1/Cip1 and SMC growth via perturbed assembly of the p21 WAF1/Cip1 -cdk4-cyclin D1 complex, thereby extending our understanding of the mechanisms of YY1-dependent repression. 1, 6 Moreover, we provide evidence that YY1 suppression of p21 WAF1/Cip1 in SMCs also involves p53 ubiquitination and proteasomal degradation ( Figure 8) .
YY1 had no effect on vascular endothelial proliferation nor did it influence p21 WAF1/Cip1 -cdk4-cyclin D1 complex assembly or pRb Ser249/Thr252 phosphorylation in this cell type. Consistent with our model, YY1 failed to alter p21 WAF1/Cip1 levels in ECs, unlike SMCs. The molecular basis for the inability of YY1 to repress p21 WAF1/Cip1 expression in ECs is not clear but may involve cell-specific differences in YY1-dependent cofactor interactions. For example, YY1 collaborates with a large number of transcription factors including RYBP (Ring1-and YY1-binding protein), 40 AP-2, 41 c-Myc, 42 YEAF1/RYBP, YAF-2, 43 as well as the general factors TBP, TAFII55, and TFIIB. 44, 45 These and/or other collaborative factors may be preferentially expressed in SMCs but not ECs. 46 Different CArG elements in the SM ␣-actin promoter confer or repress TGF-␤1 responsiveness depending on the cell type. 47 Alternatively, differences in chromatin structure and methylation state of the promoter may influence YY1's accessibility and capacity to alter transcription. YY1 has been found to bind to and recruit the histone H4 (Arg 3)-specific methyltransferase, PRMT1, to the c-myc promoter. 48 YY1 is also known to repress the human immunodeficiency virus type-1 5Ј long terminal repeat via recruitment of histone deacetylase-1 cooperatively with LSF. 49 In this study we used siRNA strategies to knock down YY1 in vivo and in vitro rather than using genetically-modified ϩ or pCB6-YY1 (0.5, 1, 2 and 3 g) together with 1 g of construct pRL-TK. Renilla luciferase activity was assessed after 24 hour. Alternatively, SMCs in 100-mm plates were transfected with 20 g of pCB6 ϩ or pCB6-YY1 (with or without E2F siRNA, 0.4 mol/L) and extracts were subjected to Western blotting after 24 hour for TK-1 or ␤-actin. c, Left panel, Ad-YY1 overexpression in the injured rat artery wall decreases p53 immunoreactivity 14 d after injury. Top right panel, SMCs in 100 mm dishes were transfected with 20 g pCB6 ϩ or pCB6-YY1 and after 12 hour, the extracts were immunoprecipitated with ubiquitin antibodies before Western blotting with p53 antibodies. Alternatively, Western blot analysis was performed for p21 WAF1/Cip1 . Lower right panel, YY1 was overexpressed in the absence or presence of 10 mol/L of MG132 and after 12 hour Western blot or RT-PCR analysis was performed for p53. *denotes P Ͻ0.05 compared with control.
mice, complementing the YY1 overexpression data and strengthening the physiological relevance of our conclusions. Mice in which YY1 is selectively ablated in vascular SMCs may be useful in response-to-injury studies of intimal thickening. However, given the critical role played by YY1 in key genes regulating SMC development such as (SM22-␣ and SM-actin) 50 the successful generation of such mice would seem unlikely. Alternatively, YY1 might be forcibly expressed in p21 WAF1/Cip1 -deficent mice, although again there is some evidence of compensatory changes by substitute factors such as p27
Kip1 and p57 Kip2 .
Studies by Sata et al have shown that intimal thickening in p21
WAF1/Cip1 -null mice does not differ from that in wild-type mice. 51 Although our data demonstrate the role of p21 WAF1/Cip1 in YY1-suppression of SMC growth and arterial wound repair via Sp1 and p53, it is still possible that p21 WAF1/Cip1 may not be the sole YY1-dependent gene responsible because YY1 is a transcription factor with multiple targets 7 and is involved in many cell regulatory systems. 2, 6 The role of other cyclins and cdks also requires exploration. This study will nonetheless facilitate further investigation into YY1-dependent processes mediating SMC growth and intimal hyperplasia. From a therapeutic standpoint, the resistance of arterial ECs to YY1-mediated growth inhibition would make YY1-based gene therapy potentially attractive in pathophysiologic situations, such as restenosis and vein grafting, where re-endothelialization is desirable and currently-used therapies, such as stent-delivered drugs [52] [53] [54] (eg, rapamycin and taxol) lack cell specificity. Moreover, recent studies demonstrate the safety of using locally-delivered adenovirus in vascular applications. Trinam EG004, which locally generates VEGF-D via an adenovirus impregnated, bio-degradable collagen-based collar akin to that used in our rabbit model (Figure 1c) , has been successfully trialed in hemodialysis patients to increase access graft patency (http://www.arktherapeutics.com/).
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None. were removed, the external carotid ligated and the incision neck closed. The rats were sacrificed 14 days later. Tissue processing and morphometry were then carried out essentially as previously described 3 . Briefly, after administering an overdose of pentobarbitone (i.p.) to the rats, the chest was opened and an 18G i.v. catheter was inserted into the heart and perfused with saline solution at 140mm Hg for 2 min. Then the vessels were fixed by perfusion with 10% formalin at the same pressure for approximately 7 min. The carotid arteries were then removed, cleaned and the ligated segment divided into three sections for embedding into paraffin, before cutting 6µm thick cross-sections. Cross-sectional areas of the media, the neointima and overall vessel size were measured using a computer-interfaced imaging system (Optimus Bioscan2, Thomas
Optical Measurement system, Inc). 5-7 rats were used in each group.
Rabbit collar model and periadventitial gene transfer. New Zealand White male rabbits (2.5-3.2 kg) were acclimatized and maintained on a normal chow diet for 1 week prior to placement of a biologically inert, silastic collar (Ark Therapeutics Ltd) around the right common carotid artery as described 4 . The contralateral carotid artery was sham operated by surgical dissection from surrounding tissues and exposed to a similar degree of stretch. The wounds were sutured and the animals allowed to gain consciousness. Five days later, the collared arteries were exposed and 100µl of each adenoviral vector solution containing 5x10 10 pfu was placed within the space between collar and artery, and the wound sutured. Nine days after gene transfer, animals were sacrificed, and collared and contralateral control arteries excised. Arteries were rinsed twice in ice-cold PBS, pH (sense strand, putative Sp1 binding site underlined) or the mutant 5' AAA GAA GCC TGT TTG TTT CGA GGT CAG CTG 3' (sense strand), respectively, into the SmaI site of pGL3-prom (Promega). Construct 3*6mSp1-7 was created using the QuickChange mutagenesis kit (Stratagene). Luciferase activity in the lysates was measured 24h after transfection using the Dual Luciferase Assay System (Promega). Firefly luciferase activity was normalized with Renilla luciferase to normalize for transfection efficiency.
Western blot analysis. Samples were resolved by electrophoresis using denaturing SDS-polyacrylamide gels for 2h at 100V. Proteins were transferred to Immobilon P ) whereas those of p21 were Frp21 ) and Rrp21 ). GAPDH primers sequences were GAP5 ( ) and GAP3 ( 5' TCC ACC ACC CTG TTG CTG TA 3' ).
EMSA analysis using nuclear extracts and recombinant proteins. SMC nuclear extracts were prepared essentially as previously described 6 and incubated with the indicated 32 P-labeled double-stranded oligonucleotide probes (150,000 cpm) in 10 mM prior to the addition of the probe. Samples were loaded onto 6% non-denaturing polyacrylamide gels and binding activity was visualized by autoradiography overnight.
Recombinant proteins were incubated with the indicated radiolabeled probes in 10mM
Tris-HCl, pH 7.5, 50mM NaCl, 1mM EDTA, 5% glycerol, 1 mg/ml BSA, 0. ).
Chromatin immunoprecipitation (ChIP) analysis. Human SMCs grown in 100-mm dishes were transfected overnight with 30 µg of the indicated plasmid(s). pcDNA-GST-YY1 was generated by digesting pGEX-2TK-GST-YY1 with HincII and ligating the blunt-ended GST-YY1 fragment into EcoRI-digested pcDNA3.1 that had also been blunt-ended. pcDNA-GST-YY1∆ZNF was generated by amplifying YY1 cDNA omitting the zinc finger region and cloning the product into pcDNA3. GCT GGC CTG CTG GAA CTC 3' and hwafsp1R 5' GGA CAC GCA GGG ACA CAC 
